Allogeneic Hematopoietic Cell Transplantation

Harnessing Expanded Antigen-Specific Donor Regulatory T Cells to Prevent GVHD in Allogeneic Hematopoietic Cell Transplantation

By MedXY 10/01/2026

A phase 1 trial demonstrates the safety and promising efficacy of expanded minor histocompatibility antigen-specific donor regulatory T cells as a novel prophylactic approach to reduce graft-versus-host disease and improve survival post-allogeneic hematopoietic cell transplantation.

Hematology-Oncology news Oncology

Personalizing Allogeneic Hematopoietic Cell Transplantation in Adult AML Using Measurable Residual Disease Testing

By MedXY 09/26/2026

Measurable residual disease (MRD) testing offers critical insights to tailor allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia, optimizing patient selection, conditioning intensity, and relapse surveillance to improve outcomes.

Hematology-Oncology news Oncology

ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry

By MedXY 09/16/2026

In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acute GvHD incidence.

Hematology-Oncology news

Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG Strategies

By MedXY 09/16/2026

A large registry analysis supports post-transplant cyclophosphamide (PTCy) as an effective alternative to anti-thymocyte globulin (ATG) for preventing graft-versus-host disease (GVHD) in reduced-intensity conditioning matched donor peripheral blood stem cell transplantation for AML and MDS.

Hematology-Oncology news Oncology

TP53 Mutations in Acute Myeloid Leukemia: Impact on Outcomes Post-Allogeneic Hematopoietic Cell Transplantation

By MedXY 09/10/2026

TP53 mutations define a high-risk AML subset with inferior survival post-allo-HCT, driven mainly by relapse. Molecular heterogeneity may guide personalized post-transplant strategies.

Hematology-Oncology news

A Comprehensive Prognostic Model for Predicting Leukemia-Free Survival Following Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia

By MedXY 07/07/2026

This article discusses a novel holistic H-score prognostic model integrating patient, disease, and treatment factors to predict leukemia-free survival after allogeneic transplantation in acute leukemia, enhancing risk stratification beyond existing models.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Early High-Resolution Immune Profiles Are Linked to Survival and Relapse After Allogeneic Stem Cell Transplantation

By MedXY 06/02/2026

Early immune profiling after allogeneic stem cell transplant was linked to survival and relapse risk. Stronger innate and adaptive immune recovery predicted better outcomes, while certain activation and checkpoint markers were associated with worse survival.

Hematology-Oncology news Oncology

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

By MedXY 06/02/2026

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and encouraging early survival outcomes.

Hematology-Oncology news Oncology

Frontline Allogeneic Transplantation Outperforms Pretransplant IPSS-M Downstaging in Myelodysplastic Neoplasms

By MedXY 05/21/2026

In adults with myelodysplastic neoplasms undergoing allogeneic transplantation, pretransplant cytoreduction modestly improved IPSS-M in some patients but did not improve post-transplant survival and was associated with higher non-relapse mortality.

Hematology-Oncology news

CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML

By MedXY 05/18/2026

Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.

Hematology-Oncology news Oncology

Molecular Profiling Refines Relapse Risk After Allogeneic Transplant in First-Remission Acute Myeloid Leukemia

By MedXY 05/11/2026

A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.

Hematology-Oncology Internal Medicine news

Blast-Phase MPNs: One-Third Achieve Long-Term Survival with Allogeneic Transplantation

By MedXY 04/21/2026

Allogeneic hematopoietic stem cell transplantation offers a potential cure for blast-phase myeloproliferative neoplasms, with one-third of patients achieving long-term survival. Key factors influencing outcomes include TP53 mutations and peripheral blast burden.

Gastroenterology Hematology-Oncology news

Enterococcus faecalis Drives MHC-II Expression in Intestinal Epithelium: A Novel Mechanism Linking Gut Microbiome Dysbiosis to Lethal Graft-versus-Host Disease

By MedXY 04/03/2026

Research reveals that Enterococcus faecalis colonization induces MHC-II expression in intestinal epithelial cells during graft-versus-host disease, with a lantibiotic-producing Blautia producta strain demonstrating potential to restore colonization resistance and improve survival outcomes.